Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $26,027,000 | $22,123,000 | $18,790,000 | $15,529,000 |
| % Growth | 17.6% | 17.7% | 21% | – |
| Cost of Goods Sold | $5,785,000 | $4,995,000 | $4,776,000 | $3,484,000 |
| Gross Profit | $20,242,000 | $17,128,000 | $14,014,000 | $12,045,000 |
| % Margin | 77.8% | 77.4% | 74.6% | 77.6% |
| R&D Expenses | $3,538,000 | $2,796,000 | $2,354,000 | $1,994,000 |
| G&A Expenses | $7,553,000 | $10,161,000 | $7,847,000 | $6,294,000 |
| SG&A Expenses | $11,085,000 | $10,161,000 | $7,847,000 | $6,294,000 |
| Sales & Mktg Exp. | $3,532,000 | $0 | $0 | $0 |
| Other Operating Expenses | -$6,000 | $105,000 | -$32,000 | -$30,000 |
| Operating Expenses | $14,617,000 | $13,062,000 | $10,169,000 | $8,258,000 |
| Operating Income | $5,625,000 | $4,066,000 | $3,813,000 | $3,733,000 |
| % Margin | 21.6% | 18.4% | 20.3% | 24% |
| Other Income/Exp. Net | -$1,218,000 | -$1,112,000 | -$492,000 | -$438,000 |
| Pre-Tax Income | $4,407,000 | $2,954,000 | $3,321,000 | $3,295,000 |
| Tax Expense | $528,000 | $546,000 | $683,000 | $616,000 |
| Net Income | $3,885,000 | $2,409,000 | $2,638,000 | $2,679,000 |
| % Margin | 14.9% | 10.9% | 14% | 17.3% |
| EPS | 11.37 | 7.39 | 8.52 | 8.67 |
| % Growth | 53.9% | -13.3% | -1.7% | – |
| EPS Diluted | 11.24 | 7.39 | 8.44 | 8.62 |
| Weighted Avg Shares Out | 341,727 | 325,981 | 309,478 | 308,899 |
| Weighted Avg Shares Out Dil | 345,562 | 325,968 | 312,455 | 310,729 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32,000 | $27,000 | $5,000 | $419,000 |
| Interest Expense | $1,239,000 | $1,111,000 | $458,000 | $0 |
| Depreciation & Amortization | $3,679,000 | $3,169,000 | $2,273,000 | $1,999,000 |
| EBITDA | $9,304,000 | $7,234,000 | $6,051,000 | $5,720,000 |
| % Margin | 35.7% | 32.7% | 32.2% | 36.8% |